Tesofensine vs BAM-15

Tesofensine and BAM-15 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.

Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.

BAM-15 is a mitochondrial protonophore (uncoupler) that dissipates the proton gradient across the inner mitochondrial membrane, converting stored energy into heat rather than ATP. Unlike older uncouplers like DNP (2,4-dinitrophenol), BAM-15 selectively uncouples mitochondria without depolarizing the plasma membrane, which dramatically improves its safety profile. In animal studies, BAM-15 reduced body fat without affecting food intake, lean mass, or core body temperature, and improved insulin sensitivity. It is not technically a peptide but is discussed alongside peptide-based metabolic therapies.

Key claims: Reduces body fat without reducing food intake; Improves insulin sensitivity; Safer than DNP as a mitochondrial uncoupler.

Both peptides are studied for: Weight Loss.

Tesofensine is also researched for: Appetite Suppression.

BAM-15 is also researched for: Metabolic Health.

Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)

BAM-15: No human safety data available Animal studies show no significant adverse effects at effective doses Does not increase core body temperature in mice (unlike DNP)